

Sheppard Mullin Represented Laidlaw in Connection with NLS Pharmaceuticals' Private Placements

12.14.2022

Sheppard Mullin served as counsel to Laidlaw & Company (UK) Ltd., as introducing broker, in connection with NLS Pharmaceuticals', a Swiss clinical-stage biopharmaceutical company, \$30 million private placement with marquee life sciences investor, Biotechnology Value Fund, BVF Partners L.P. The transaction closed on December 13, 2022.

Sheppard Mullin also represented Laidlaw, as sole placement agent, in NLS Pharmaceuticals' \$4 million private placement with investors, alongside participation from the company's Chairman of the Board of Directors, Ronald Hafner, and George Apostol, the company's recently appointed Chief Medical Officer. This transaction closed on October 7, 2022.

The Sheppard Mullin deal team was led by Richard Friedman and included Stephen Cohen and Gregory Carney.

[Click here](#) and [here](#) to view the press releases.